Cytek Biosciences (NASDAQ:CTKB) Issues Quarterly Earnings Results

Cytek Biosciences (NASDAQ:CTKB) posted its earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09), FiscalAI reports. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. The firm had revenue of $48.14 million during the quarter, compared to analysts’ expectations of $47.31 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q2 revenue increased 6% year over year to $48.1 million, driven by 18% growth in the U.S., strong double-digit growth in China, high-end FSP instrument sales, and continued service momentum. Management raised the low end of full-year 2026 revenue guidance to $207 million-$212 million.
• Recurring revenue continued to strengthen, with service revenue up 10% to $15.6 million and combined reagents and service revenue representing 35% of trailing-12-month revenue. Cytek expects adjusted EBITDA to improve in the second half and reach approximately breakeven for full-year 2026.
• Cytek launched the Borealis, a 60-color, seven-laser full spectral-flow cytometer, and expanded Aurora Evo automation capabilities for biopharma and CRO laboratories. Management said early customer feedback on Borealis has been strong and believes the products can support future market-share gains.
• Regional and profitability pressures persisted: EMEA revenue declined approximately 8% amid government budget constraints, while GAAP net loss widened to $12.2 million from $5.6 million a year earlier. Operating expenses rose 15%, including higher legal costs tied to patent litigation and increased personnel expenses.
• The company began reorganizing into three customer-aligned business units—Solutions and Clinical, Research Technology, and Service—aiming to improve market penetration and growth, particularly in mid- and low-end instruments, reagents, and clinical applications. Management said the benefits will take time to materialize and are already incorporated into 2026 guidance.

Cytek Biosciences Price Performance

CTKB stock traded down $0.06 during trading on Thursday, reaching $4.12. 404,712 shares of the stock traded hands, compared to its average volume of 1,022,518. Cytek Biosciences has a 52-week low of $3.28 and a 52-week high of $6.18. The business’s 50 day moving average price is $4.31 and its 200-day moving average price is $4.42. The firm has a market capitalization of $532.70 million, a PE ratio of -7.22 and a beta of 1.17.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytek Biosciences in a report on Wednesday, June 24th. Morgan Stanley reduced their price objective on Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, Stephens decreased their price objective on Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cytek Biosciences has a consensus rating of “Hold” and a consensus price target of $5.69.

Institutional Investors Weigh In On Cytek Biosciences

Large investors have recently added to or reduced their stakes in the company. Boston Partners bought a new position in shares of Cytek Biosciences during the third quarter worth about $129,000. BNP Paribas Financial Markets raised its position in shares of Cytek Biosciences by 98.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 23,816 shares of the company’s stock valued at $83,000 after acquiring an additional 11,838 shares in the last quarter. Quantbot Technologies LP increased its stake in Cytek Biosciences by 37.1% during the third quarter. Quantbot Technologies LP now owns 33,907 shares of the company’s stock valued at $118,000 after purchasing an additional 9,176 shares during the last quarter. Cerity Partners LLC bought a new position in shares of Cytek Biosciences in the 2nd quarter worth about $175,000. Finally, Strs Ohio bought a new stake in shares of Cytek Biosciences during the 1st quarter valued at about $105,000. 69.46% of the stock is owned by institutional investors and hedge funds.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.